Nasus Pharma Ltd. (NSRX)
NYSE: NSRX · Pharmaceutical Preparations · Tel Aviv - Yafo, IL · filing with the SEC since 2024
Who owns Nasus Pharma Ltd.
As filed with the SECHolders of 5% or more
6
Udi Gilboa holds 21.1% of Ordinary Shares, as its SCHEDULE 13G filed Nov 10, 2025 says.
Directors and officers
9
report now, of 9 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Udi Gilboa
SCHEDULE 13G · filed Nov 10, 2025 · Ordinary Shares
Dr. Dalia Megiddo
SCHEDULE 13G · filed Nov 12, 2025 · Ordinary Shares
Dr. Ronnie Hershman
SCHEDULE 13G · filed Nov 13, 2025 · Ordinary Shares
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 9.99% in May 15, 2026
Capital Point Ltd.
SCHEDULE 13G · filed Aug 20, 2025 · Ordinary Shares, no par value
Funicular Funds, LP
SCHEDULE 13G · filed Apr 7, 2026 · Ordinary Shares
What NSRX reports owning in othersstakes of 5% or more, and other ties
Nasus Pharma Ltd. reports no stake in another company in the record.
Insider tradesForm 4
0sales
3purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 10 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Teleman Dan Benjamin | Chief Executive Officer | 0 | $0 | 0 | 3 | $100,000 |